Innovent Announced Clinical Data of Multiple Trials Will be

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

Jilin , China , Taiwan , Shanghai , United States , Hong Kong , Zhejiang , Suzhou , Jiangsu , Qian Jiang , Hubei , Ying Cheng , Peking , Beijing , Macau , Chinese , American , Innovent Biologics , Eli Lilly , Selpercatinib Eli Lilly , Adimab Incyte , Zhijian Xiao , Miao , Caicun Zhou , Union Medical College , School Of Medicine , Institute Of Hematology Blood Diseases Hospital , Prnewswire Innovent Biologics Inc , Md Anderson Cancer Center , University Institute Of Hematology , University People Hospital , First Affiliated Hospital Of Suzhou University , Zhejiang University , Chinese Academy Of Medical Sciences , Incyte Corporation , Professor Caicun Zhou , Shanghai Pulmonary Hospital , First Affiliated Hospital , Combination With Sintilimab , Selected Non Small Cell Lung Cancer , Professor Ying Cheng , Jilin Cancer , Professor Zhijian Xiao , Blood Diseases Hospital , Chinese Academy , Medical Sciences , Peking Union Medical College , Updated Results , Pivotal Phase , Tyrosine Kinase Inhibitor , Accelerated Phase Chronic Myeloid Leukemia , Professor Qian Jiang , Peking University Institute , Peking University People , Five Year Follow Up , Novel Third Generation , Kinase Inhibitor , Resistant Chronic Myeloid Leukemia , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , Mainland China ,